Leqembi efficacy doubts in APOE4 subgroups raise regulatory and commercial risks for Eisai and Biogen; see real-world data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results